Trial Profile
A 2-Stage Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Tablets in Healthy Subjects in a Double-blind, Placebo-controlled, Multiple-ascending-dose Stage and an Open-label, Single-dose, Crossover Food-effect Stage
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Olinciguat (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ironwood Pharmaceuticals
- 12 Dec 2017 Results of multiple-ascending dose part of this study presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 20 Dec 2016 Status changed from active, no longer recruiting to completed.
- 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2016.